Clinical Practice Guidelines for the management of locally advanced ...

19. Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M. Effects of continued androgendeprivation
therapy and other prognostic factors on response and survival in phase II
chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group
report. Journal of Clinical Oncology 12(9):1868-75, 1994.
20. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with
mitoxantrone and prednisone for advanced refractory prostate cancer. New England Journal
of Medicine 351(15):1513-20, 2004.
21. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in
women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled
trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17(3):846-854.
22. Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal
complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia
Breast Cancer Study Group. N Engl J Med 1996;335(24):1785-1791.
23. Coleman RE. Should bisphosphonates be the treatment of choice for metastatic bone disease?
Semin Oncol 2001;28(4 Suppl 11):35-41.
24. Clarke NW, Holbrook IB, McClure J, George NJ. Osteoclast inhibition by pamidronate in
metastatic prostate cancer: a preliminary study. Br J Cancer 1991;63(3):420-423.
25. Percival RC, Urwin GH, Harris S et al. Biochemical and histological evidence that carcinoma
of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987;13(1):41-
49.
26. Taube T, Kylmala T, Lamberg-Allardt C, Tammela TL, Elomaa I. The effect of clodronate on
bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised
placebo-controlled study. Eur J Cancer 1994;30A(6):751-758.
27. Fernandez-Conde M, Alcover J, Aaron JE, Ordi J, Carretero P. Skeletal response to clodronate
in prostate cancer with bone metastases. Am J Clin Oncol 1997;20(5):471-476.
28. Dearnaley DP, Sydes MR, Mason MD et al. A double-blind, placebo-controlled, randomized
trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer
Inst 2003;95(17):1300-1311.
29. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid
in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst
2002;94(19):1458-1468.
30. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention
of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl
Cancer Inst 2004;96(11):879-882.
31. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two
multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation
of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21(23):4277-4284.
32. Figg WD, Liu Y, Arlen P et al. A randomized, phase II trial of ketoconazole plus alendronate
versus ketoconazole alone in patients with androgen independent prostate cancer and bone
metastases. J Urol 2005;173(3):790-796.
Clinical practice guidelines for the management of locally advanced and metastatic prostate cancer
92